The US Centers for Medicare and Medicaid Services’ national coverage determination limiting Medicare coverage for Biogen, Inc./Eisai Co., Ltd.’s Aduhelm (aducanumab-avwa) to situations when patients are enrolled in a clinical trial should not be read as a sign that the agency is cracking down on drugs cleared through the US Food and Drug Administration’s accelerated approval pathway, CMS chief medical officer Lee Fleisher emphasized.
“Our recent decision should not be viewed as setting a new direction on therapies that receive FDA accelerated approval,” Fleisher said 12 April during the Duke-Margolis Inaugural Health Policy Conference. CMS has covered "quite a few" drugs for diseases such as HIV and cancer that have received accelerated approval to date, he pointed out
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?